| Literature DB >> 27693711 |
Adriana Isvoran1, Maxime Louet2, Diana Larisa Vladoiu1, Dana Craciun3, Marie-Anne Loriot4, Bruno O Villoutreix2, Maria A Miteva5.
Abstract
Pharmacogenomics investigates DNA and RNA variations in the human genome related to drug responses. Cytochrome P450 (CYP) is a supergene family of drug-metabolizing enzymes responsible for the metabolism of approximately 90% of human drugs. Among the major CYP isoforms, the CYP2C subfamily is of clinical significance because it metabolizes approximately 20% of clinically administrated drugs and represents several variant alleles leading to adverse drug reactions or altering drug efficacy. Here, we review recent progress on understanding the interindividual variability of the CYP2C members and the functional and clinical impact on drug metabolism. We summarize current advances in the molecular modeling of CYP2C polymorphisms and discuss the structural bases and molecular mechanisms of amino acid variants of CYP2C members that affect drug metabolism.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27693711 DOI: 10.1016/j.drudis.2016.09.015
Source DB: PubMed Journal: Drug Discov Today ISSN: 1359-6446 Impact factor: 7.851